TSC22D3 and systemic lupus erythematosus: Similarly, in SLE patients, a known systemic autoimmune disease, it has been shown that higher GILZ levels are associated with clinical response to glucocorticoid treatment, while reduced induction of GILZ by glucocorticoids is associated with increased disease activity, suggesting that GILZ induction is considered a marker of glucocorticoid treatment13.